GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
GRI Bio (NASDAQ: GRI) will present at the Virtual Investor Pitch Conference on June 18, 2024, at 11:00 AM ET. The company specializes in developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. During the event, CEO Marc Hertz, PhD, will deliver an elevator pitch and discuss upcoming milestones. Attendees can submit questions live, with responses given within the allotted time. The live video webcast and a replay available for 90 days can be accessed on GRI Bio's website.
- GRI Bio's participation in the Virtual Investor Pitch Conference provides a platform to communicate directly with potential investors.
- CEO Marc Hertz will outline upcoming milestones, offering transparency and future direction for the company.
- The live Q&A session allows for investor engagement and immediate feedback.
- A webcast replay available for 90 days increases accessibility for investors who cannot attend live.
- The PR lacks specific financial data or clinical trial results that could offer a clearer picture of the company's current performance.
- No new product launches or partnerships were announced, which might have provided a stronger catalyst for stock movement.
Live video webcast on Tuesday, June 18th at 11:00 AM ET
LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 11:00 AM ET.
As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
What is the date and time for GRI Bio's presentation at the Virtual Investor Pitch Conference?
Who will present at the Virtual Investor Pitch Conference on behalf of GRI Bio?
What type of diseases is GRI Bio targeting with its NKT cell modulators?
Will there be an opportunity for investors to ask questions during GRI Bio's presentation?
How can I access the live video webcast of GRI Bio's presentation?
How long will the replay of GRI Bio's presentation be available?
